MX380022B - Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas - Google Patents

Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas

Info

Publication number
MX380022B
MX380022B MX2018013742A MX2018013742A MX380022B MX 380022 B MX380022 B MX 380022B MX 2018013742 A MX2018013742 A MX 2018013742A MX 2018013742 A MX2018013742 A MX 2018013742A MX 380022 B MX380022 B MX 380022B
Authority
MX
Mexico
Prior art keywords
crisaborole
free form
preparation
crystal forms
relates
Prior art date
Application number
MX2018013742A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013742A (es
Inventor
Fei Lu
Minhua Chen
Nan Xia
Xiaoyu Zhang
Yanfeng Zhang
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60266671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX380022(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of MX2018013742A publication Critical patent/MX2018013742A/es
Publication of MX380022B publication Critical patent/MX380022B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
MX2018013742A 2016-05-09 2017-05-09 Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas MX380022B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610301832 2016-05-09
PCT/CN2017/083631 WO2017193914A1 (zh) 2016-05-09 2017-05-09 克立硼罗游离形式的晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2018013742A MX2018013742A (es) 2019-08-01
MX380022B true MX380022B (es) 2025-03-11

Family

ID=60266671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013742A MX380022B (es) 2016-05-09 2017-05-09 Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas

Country Status (13)

Country Link
US (1) US11773113B2 (enExample)
EP (1) EP3456722B1 (enExample)
JP (3) JP2019520321A (enExample)
KR (1) KR102221472B1 (enExample)
CN (2) CN108884111A (enExample)
AU (1) AU2017262235C1 (enExample)
BR (1) BR112018073017B1 (enExample)
CA (1) CA3023851C (enExample)
IL (1) IL262878A (enExample)
MX (1) MX380022B (enExample)
SG (1) SG11201809984PA (enExample)
WO (1) WO2017193914A1 (enExample)
ZA (1) ZA201807892B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329311B1 (en) * 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
BR112020013794B1 (pt) * 2018-01-09 2023-05-02 Halcyon Labs Private Limited Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN110780005B (zh) * 2019-11-14 2022-07-29 江苏海岸药业有限公司 一种克立硼罗原料及其合成中间体的分析方法
CN111983123A (zh) * 2020-08-14 2020-11-24 江苏海岸药业有限公司 用于治疗皮肤疾病的克立硼罗制剂的体外评价方法
CN112375093A (zh) * 2020-11-13 2021-02-19 江苏知原药业股份有限公司 一种克立硼罗晶型化合物及其制备方法
CN113087733A (zh) * 2021-04-06 2021-07-09 南京科默生物医药有限公司 克立硼罗的晶型a、晶型b、晶型c、晶型d、晶型e及其制备方法
WO2024047571A1 (en) * 2022-09-01 2024-03-07 Savoi Guilherme Crisaborole cocrystal derivatives
CN115417890A (zh) * 2022-09-24 2022-12-02 中山万远新药研发有限公司 克立硼罗的新晶型及其制备方法与用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (enExample) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
HUE026021T2 (en) * 2005-02-16 2016-05-30 Anacor Pharmaceuticals Inc Biocidal boron phthalide (boronophthalide) compounds
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
CN101505603A (zh) * 2005-12-30 2009-08-12 安纳考尔医药公司 含硼的小分子
BRPI0708051A2 (pt) * 2006-02-16 2011-05-17 Anacor Pharmaceuticals Inc moléculas pequenas contendo boro como agentes antiflamatórios
RU2008152367A (ru) * 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR101672511B1 (ko) * 2008-03-06 2016-11-03 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
PL3383363T3 (pl) * 2015-11-30 2021-05-31 Anacor Pharmaceuticals, Inc. Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem
WO2017203514A1 (en) * 2016-05-26 2017-11-30 Perrigo Api Ltd Polymorphs of crisaborole and production processes therefor

Also Published As

Publication number Publication date
CN119751489A (zh) 2025-04-04
IL262878A (en) 2018-12-31
NZ786020A (en) 2025-06-27
EP3456722B1 (en) 2025-12-10
WO2017193914A1 (zh) 2017-11-16
BR112018073017B1 (pt) 2022-06-14
BR112018073017A2 (pt) 2019-02-19
CA3023851C (en) 2021-01-26
AU2017262235C1 (en) 2020-08-20
JP2023116645A (ja) 2023-08-22
RU2018142490A3 (enExample) 2020-06-10
ZA201807892B (en) 2021-06-30
CA3023851A1 (en) 2017-11-16
MX2018013742A (es) 2019-08-01
CN108884111A (zh) 2018-11-23
US20230234974A1 (en) 2023-07-27
US11773113B2 (en) 2023-10-03
EP3456722A4 (en) 2019-12-18
SG11201809984PA (en) 2018-12-28
NZ748385A (en) 2022-03-25
AU2017262235B2 (en) 2019-09-19
JP2021167327A (ja) 2021-10-21
EP3456722A1 (en) 2019-03-20
RU2018142490A (ru) 2020-06-10
KR20190005195A (ko) 2019-01-15
KR102221472B1 (ko) 2021-03-02
AU2017262235A1 (en) 2018-12-06
JP2019520321A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
MX380022B (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CR20170146A (es) Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-yl)piperidin-1-il]pirimidina-2,4-diamina
CL2015003117A1 (es) Modificaciones en la estructura cristalina
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
MX2019015744A (es) Composiciones farmaceuticas.
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX2020004540A (es) Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
BR112021011124A2 (pt) Anelossomos e métodos de uso
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
UY36250A (es) Forma cristalina de sofosbuvir y proceso para su preparación
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).